Developer docs
API playgroundTry for free, no card

Search company profiles

Formosa Pharmaceuticals

Full company profile

uuid0003bfk

Namestring
Formosa Pharmaceuticals
Legal namestring
Formosa Pharmaceuticals, Inc.
Company typeenum
Public
Founded yearint
2011
Descriptiontext

Formosa Pharmaceuticals (TWSE: 6838) is a clinical-stage biopharmaceutical company headquartered in Taipei, Taiwan, founded in 2010/2011 with approximately 19 employees as of end-2024. The company applies a dual-platform "Double A" strategy spanning ophthalmology and oncology. Its proprietary APNT® (Active Pharmaceutical Nanoparticle Technology) platform — acquired from Activus Pharma (Japan) in 2019 — reduces water-insoluble APIs to sub-200nm particle sizes using GRAS-listed grinding media, enabling homogeneous nanosuspensions for topical ocular, oral, and inhalation administration without organic solvents or刺激性 additives. The lead asset APP13007 (clobetasol propionate ophthalmic suspension 0.05%) received FDA approval in March 2024 as the first new ophthalmic steroid approved by the FDA in over 15 years, followed by Health Canada approval in March 2026 and commercial launch in the US in September 2024.

The oncology pipeline includes TSY-110 (a Kadcyla biosimilar co-developed with EirGenix for HER2-positive breast cancer) and TSY-310 (a first-in-class bispecific ADC targeting EGFR/ROR1, in-licensed from Almac Discovery in May 2025 and presented at ASCO 2026). Additional APNT-platform candidates include APP13002 (antibiotic 505(b)(2) formulation) and earlier-stage TSY-120, TSY-210, and MPT0E028 programs.

Formosa operates a capital-efficient, asset-light out-licensing business model, signing exclusive territorial licensing agreements with regional pharmaceutical majors (Harrow for the US, China Grand Pharma for Greater China, Samil for Korea/Vietnam, Arrotex for Australia/NZ, Cipla for 11 emerging markets, Adalvo for 39 European countries plus Brazil, among others) covering 60+ countries. The company receives upfront payments, regulatory and sales milestones, and royalties on net sales while retaining contract manufacturing responsibilities through Pharmasutics (Taoyuan, Taiwan). The company listed on the TWSE in August 2024 and has received multiple Taiwan biotech innovation awards (Taipei Biotech Awards, Taiwan BIO Awards) in 2022-2024.

Short descriptiontext

Formosa Pharmaceuticals is a Taiwan-based clinical-stage biopharmaceutical company (TWSE: 6838) that develops ophthalmology and oncology drugs using its proprietary APNT® nanoparticle platform, commercializing its FDA-approved lead product APP13007 through a global out-licensing model covering 60+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTaipei, Taiwan
HQ citystring
Taipei
HQ countrystring
Taiwan
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic pharmaceuticals, nanoparticle drug formulation, antibody-drug conjugates, biopharmaceutical licensing, post-surgical steroid therapies
Industry3 codes
PRIMARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • Ophthalmic Goods3851
Product category
Ophthalmic Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing Revenue (Upfront, Milestones, Royalties)
TypeLicensing Royalties
Description

Formosa receives upfront payments, regulatory milestones, sales milestones, and ongoing royalties based on net sales of licensed products (primarily APP13007) across global territories. Licensing agreements signed with partners in US (Harrow), China (China Grand Pharma), South Korea (Samil), Australia/New Zealand (Arrotex), EU/Brazil (Adalvo), Canada/Mexico (Apotex), and others.

formosapharma.com
2Contract Manufacturing Supply
TypeHardware Sales
Description

Formosa manufactures and supplies finished APP13007 product to licensing partners (e.g., Eyenovia/Harrow in US). Taiwan FDA (TFDA) granted export permit for US shipments. Manufacturing carried out by contract partners including Baudax Bio (formerly SpecGx) for API supply and Pharmasutics (Taoyuan facility) for fill-finish.

formosapharma.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels14 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Pricing details1 tier
1Licensing deal terms include upfront payment, regulatory milestones, sales milestones, and royalties on net sales.
ModelOtherBilling cadenceMulti-year contract
Notes

Agreement with China Grand Pharma includes upfront payment, regulatory and sales milestones, and royalties based on future net sales. Eyenovia licensing deal valued at up to USD 86 million including signing fee, development milestones, and sales milestones.

formosapharma.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1APNT®
Description

Active Pharmaceutical (ingredient) Nanoparticle Technology - proprietary nanoparticle formulation platform for enhancing dissolution and bioavailability of APIs

formosapharma.com
+3 more records
Core offering1 text field

Formosa Pharmaceuticals is a clinical-to-commercial stage biopharmaceutical company that develops, manufactures, and out-licenses ophthalmology and oncology therapeutics built on two proprietary platforms: the APNT® nanoparticle formulation technology and a bispecific antibody-drug conjugate (ADC) platform. Its lead commercial product is APP13007 (clobetasol propionate ophthalmic suspension 0.05%), an FDA-approved corticosteroid nanosuspension for post-operative ocular inflammation and pain following cataract surgery. Pipeline assets include APP13002 (antibiotic ocular formulation), TSY-110 (Kadcyla biosimilar), TSY-120, TSY-310 (EGFR/ROR1 bispecific ADC), and TSY-210 (anti-infective program).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 80% of patients achieved complete pain relief within 4 days post-surgery (vs 50% with placebo); 60% achieved complete anterior chamber cell clearance (ACC=0) from POD8 sustained to POD15 (vs 4% placebo)
+3 more records
Product overview1 text field

Formosa Pharmaceuticals is a clinical-stage biopharmaceutical company with a dual focus strategy ("Double A" strategy) encompassing ADC (antibody-drug conjugate) and APNT (nanoparticle) platforms. The product portfolio includes: APP13007, an FDA-approved ophthalmic corticosteroid for post-surgical inflammation and pain; APP13002, an antibiotic formulation for infectious eye diseases; TSY-110, a Kadcyla biosimilar for HER2-positive breast cancer; and TSY-310, a first-in-class bispecific ADC targeting EGFR/ROR1 for solid tumors. All ophthalmic products are powered by the proprietary APNT nanoparticle technology platform, which enables enhanced drug delivery through improved dissolution and bioavailability.

Product and service6 records
1APP13007 (Clobetasol Propionate Ophthalmic Suspension 0.05%)
CategoryOphthalmic corticosteroid drug product
Description

FDA-approved topical corticosteroid nanosuspension derived from the proprietary APNT® nanoparticle formulation platform, delivered as a twice-daily dosing regimen for 14 days, indicated for the treatment of inflammation and pain following ocular surgery, particularly cataract surgery. Approved by FDA (March 2024) and Health Canada (March 2026). Phase 3 trials showed 80% of patients pain-free by day 4 and 60% achieving complete anterior chamber cell clearance (ACC=0) sustained from POD8 to POD15, with less than 2% adverse event rate.

2APP13002
CategoryOphthalmic anti-infective drug product
Description

Antibiotic 505(b)(2) formulation developed using the APNT® nanoparticle technology platform for infectious eye diseases, designed to enhance drug delivery for ocular infections.

3TSY-110 (ado-trastuzumab emtansine biosimilar)
CategoryOncology ADC biosimilar
Description

HER2-positive antibody-drug conjugate (ADC) biosimilar referencing Kadcyla® for treatment of metastatic HER2-positive breast cancer, developed using advanced antibody and bioconjugation technology through Taiwanese CDMO partners.

4TSY-310 (ALM-401)
CategoryOncology bispecific ADC
Description

First-in-class bispecific antibody-drug conjugate targeting both EGFR and ROR1 for the treatment of solid tumors, including non-small cell lung cancer (NSCLC). Features enhanced internalization and bystander cytotoxicity to address limitations of traditional single-target therapies.

5TSY-120
CategoryOncology ADC pipeline asset
Description

ADC pipeline asset within Formosa Pharmaceuticals' antibody-drug conjugate pipeline.

6TSY-210 (抗感染研發專案 | Anti-Infective R&D Project)
CategoryAnti-infective R&D program
Description

Anti-infective research and development program within Formosa Pharmaceuticals' pipeline, focused on infectious disease therapeutics.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership21 partners
1Samil Pharmaceutical Co., Ltd.
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-01
Description

Exclusive licensing agreement for commercialization of APP13007 in Vietnam. Building on January 2026 South Korea license. Deal includes upfront payment, regulatory milestones, and royalties. Vietnam has 300,000 cataract surgeries annually with 5% growth; ophthalmic corticosteroid market valued at $4.26 million USD in 2024. Samil pursuing regulatory approval and launch preparations in both markets.

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-01
Description

Strategic research collaboration announced April 30, 2026, to develop next-generation ophthalmic formulations for corneal and ocular surface diseases using Formosa's APNT® nanoparticle technology. Combines SERI's clinical research expertise (led by Associate Professor Yu-Chi Liu) with Formosa's drug delivery platform to enhance efficacy, bioavailability, and safety of topical ocular therapies.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-01
Description

Exclusive licensing agreement for commercialization of APP13007 in Australia and New Zealand. Deal includes upfront payments, regulatory milestones, sales milestones, and royalty considerations. Territory represents approximately 250,000 cataract surgeries annually. Arrotex fulfills 50% of Australia's total pharmaceutical volume and will leverage its national ophthalmology infrastructure.

4Samil Pharmaceutical Co., Ltd.
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-01
Description

Exclusive licensing agreement for commercialization of APP13007 (clobetasol propionate ophthalmic suspension) in South Korea. Samil is a Korean pharmaceutical manufacturer (000520.KS) founded in 1947, specializing in ophthalmology, gastroenterology, and CNS. ~800,000 cataract surgeries annually in South Korea. Agreement includes upfront payment, sales milestones, and royalties. APP13007 is the first ophthalmic steroid to enter the Korean market since 2008.

prnewswire.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-01
Description

Exclusive licensing for major ASEAN markets: Singapore, Thailand, Indonesia, Philippines. Rxilient is a Singapore-based pharma company focused on emerging markets in Southeast Asia, Hong Kong, Macau, Taiwan, and MENA, with focus on ophthalmology, oncology, immunology, and internal medicine.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-06-01
Description

Exclusive licensing agreement for US market commercialization of APP13007 (marketed as BYQLOVI™). Previously partnered with Eyenovia; rights transferred to Harrow in 2025. Harrow (NASDAQ: HROW) is a leading US ophthalmic pharmaceutical company. ~700,000 ophthalmic surgeries annually drive a ~USD 1.3 billion market.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-05-01
Description

Licensing for 39 European countries plus Brazil. Adalvo is a leading European B2B pharmaceutical company with partnerships in 130+ countries. European markets include UK, France, Germany, Spain, Italy, and other EU member states.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-01
Description

In-licensing of ALM-401 (renamed TSY-310), a first-in-class bispecific ADC targeting EGFR/ROR1 for treatment of solid tumors including NSCLC. This adds a novel bispecific ADC to Formosa's oncology pipeline alongside TSY-110 (Kadcyla biosimilar).

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-04-01
Description

Exclusive licensing for Chile and 8 emerging Latin American markets: Bolivia, Costa Rica, Guatemala, El Salvador, Honduras, Paraguay, Peru, Panama. Saval (headquartered in Santiago, Chile) operates across 14 Latin American countries with 85+ years of history.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-03-01
Description

Multi-regional licensing for 11 emerging markets: India, Nepal, Sri Lanka, Bangladesh, Malaysia, Myanmar, Kenya, Nigeria, South Africa, Argentina, Colombia. Cipla is India's 3rd largest pharma company, #1 in South Africa prescription market, and #4 in US generics market.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-11-01
Description

Exclusive licensing for Swiss market. Medvisis specializes in innovative medicines, rare disease treatments, and hospital pharmaceuticals, focusing on product registration and market access.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-10-01
Description

Exclusive licensing for Portuguese market. DÁVI is a century-old company and major player in ophthalmology and ENT in Portugal. Partner of Pfizer for over 10 years (Xalacom, Xalatan). ~90,000 cataract surgeries annually in Portugal.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-09-01
Description

API (active pharmaceutical ingredient) supply for APP13007. Baudax Bio (formerly SpecGx, a subsidiary of Mallinckrodt) supplies clobetasol propionate API for the FDA-approved ophthalmic suspension.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-08-01
Description

Exclusive licensing for Canadian market. Apotex is Canada's largest pharmaceutical company. Expanded to include Mexico in 2025.

15Pharmasutics (Taoyuan) / Baudax Group
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-06-01
Description

Contract fill-finish manufacturing for APP13007. Pharmasutics (景德製藥) in Taoyuan, part of Baudax Group, handles filling and packaging of the ophthalmic suspension for US export. TFDA export permit obtained September 2024; first shipment to US completed September 2024.

formosapharma.com
16AimMax Therapeutics, Inc.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-01
Description

US-based co-development partner for APP13007 clinical development. Joint NDA submission to FDA (May 2023), which was accepted July 2023 with PDUFA date of March 4, 2024. AimMax contributed to clinical trial design, regulatory strategy, and FDA interactions. FDA approval obtained March 2024. AimMax is based in Research Triangle Park, North Carolina.

formosapharma.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-05-01
Description

Exclusive licensing for Middle East and North Africa (17 countries). Tabuk is a leading Saudi Arabian pharmaceutical company with manufacturing facilities in Saudi Arabia, Sudan, and Algeria, and 2,400+ employees.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-01
Description

Exclusive licensing for Brazilian market. Cristália is a Brazilian pharmaceutical company.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-02-01
Description

Development collaboration combining Formosa's APNT® nanoparticle formulation platform with Eyenovia's Optejet® microdose drug delivery technology (MAP™ - Microdose Array Print). Co-development of acute dry eye disease treatment using clobetasol ophthalmic suspension with Optejet device. Started August 2024 in the US.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-03-01
Description

Co-development alliance to develop TSY-0110 (EG12043 ado-trastuzumab emtansine biosimilar, Kadcyla®) for HER2-positive breast cancer. Taiwan's two major biopharma CDMOs provided antibody and bioconjugation technology.

21China Grand Pharmaceutical and Healthcare Holdings Limited
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-06-01
Description

Exclusive licensing agreement for APP13007 in Mainland China, Hong Kong, and Macau. China Grand Pharma (HKEX: 00512) is one of China's largest ophthalmology companies with ~30 ophthalmic products covering prescription drugs, OTC, devices, and consumer health. NDA Phase 3 trial initiated in China Q4 2024.

formosapharma.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Aldeyra Therapeutics is a clinical-stage biotech developing novel treatments for ocular inflammatory diseases (dry eye, allergic conjunctivitis). Comparable as a small-cap ophthalmic-focused biotech with innovative therapeutics targeting post-operative and chronic ocular inflammation.

TypeDirect peer
Description

Tarsus Pharmaceuticals is a US biopharmaceutical company developing and commercializing novel therapeutics for eye diseases, including post-surgical and ocular surface conditions. Comparable as a small-cap specialty ophthalmic pharma with a recently commercialized product in similar therapeutic indications.

TypeDirect peer
Description

Ocular Therapeutix is a US-based biopharmaceutical company developing therapies for eye diseases using a proprietary hydrogel technology platform. Comparable as a small ophthalmic pharma commercializing innovative drug delivery-based products in the same therapeutic categories.

TypeDirect peer
Description

Ocugen is a US-based biopharmaceutical company developing gene therapies and novel biologics for ophthalmic diseases. Comparable as a small-cap ophthalmic-focused biotech with a multi-platform strategy and global licensing ambitions.

TypeDirect peer
Description

Kala Bio is a clinical-stage biopharmaceutical company developing novel therapies for eye diseases using a proprietary mucus-penetrating particle technology platform. Comparable as a small ophthalmic biotech leveraging a differentiated drug delivery technology platform.

TypeDirect peer
Description

Eyenovia is a US ophthalmic therapeutics company that was Formosa's original US development partner for APP13007 (using its Optejet® microdose delivery platform). Comparable as a small-cap ophthalmic specialty pharma with innovative delivery approaches targeting the same prescriber base.

TypeDirect peer
Description

Harrow Health (NASDAQ: HROW) is a US specialty ophthalmic pharmaceutical company that is both Formosa's US commercial partner for APP13007 (BYQLOVI™) and a comparable specialty ophthalmic pharma focused on commercializing innovative therapies in the same end market.

TypeDirect peer
Description

Nicox is a European specialty ophthalmic pharmaceutical company developing therapeutics for ocular conditions including glaucoma and dry eye. Comparable as a small-to-mid cap specialty ophthalmic pharma with similar licensing-driven business model and end-market focus.

TypeEmerging player
Description

Aurinia Pharmaceuticals is a small-cap biopharma that has commercialized a specialty therapeutic (voclosporin) through global licensing deals with partners like Otsuka. Comparable business model of out-licensing a single approved asset to global commercial partners for milestone/royalty economics.

10Samil Pharmaceutical
TypeRegional player
Description

Samil Pharmaceutical (000520.KS) is a Korean pharmaceutical manufacturer that became Formosa's exclusive licensee for APP13007 in Korea and Vietnam. Comparable as a regional specialty pharma with ophthalmology focus, though primarily a partner rather than direct competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Formosa Pharmaceuticals

Ophthalmic Pharmaceuticalsformosapharma.com

Formosa Pharmaceuticals is a Taiwan-based clinical-stage biopharmaceutical company (TWSE: 6838) that develops ophthalmology and oncology drugs using its proprietary APNT® nanoparticle platform, commercializing its FDA-approved lead product APP13007 through a global out-licensing model covering 60+ countries.

What Formosa Pharmaceuticals does

Formosa Pharmaceuticals (TWSE: 6838) is a clinical-stage biopharmaceutical company headquartered in Taipei, Taiwan, founded in 2010/2011 with approximately 19 employees as of end-2024. The company applies a dual-platform "Double A" strategy spanning ophthalmology and oncology. Its proprietary APNT® (Active Pharmaceutical Nanoparticle Technology) platform — acquired from Activus Pharma (Japan) in 2019 — reduces water-insoluble APIs to sub-200nm particle sizes using GRAS-listed grinding media, enabling homogeneous nanosuspensions for topical ocular, oral, and inhalation administration without organic solvents or刺激性 additives. The lead asset APP13007 (clobetasol propionate ophthalmic suspension 0.05%) received FDA approval in March 2024 as the first new ophthalmic steroid approved by the FDA in over 15 years, followed by Health Canada approval in March 2026 and commercial launch in the US in September 2024.

The oncology pipeline includes TSY-110 (a Kadcyla biosimilar co-developed with EirGenix for HER2-positive breast cancer) and TSY-310 (a first-in-class bispecific ADC targeting EGFR/ROR1, in-licensed from Almac Discovery in May 2025 and presented at ASCO 2026). Additional APNT-platform candidates include APP13002 (antibiotic 505(b)(2) formulation) and earlier-stage TSY-120, TSY-210, and MPT0E028 programs.

Formosa operates a capital-efficient, asset-light out-licensing business model, signing exclusive territorial licensing agreements with regional pharmaceutical majors (Harrow for the US, China Grand Pharma for Greater China, Samil for Korea/Vietnam, Arrotex for Australia/NZ, Cipla for 11 emerging markets, Adalvo for 39 European countries plus Brazil, among others) covering 60+ countries. The company receives upfront payments, regulatory and sales milestones, and royalties on net sales while retaining contract manufacturing responsibilities through Pharmasutics (Taoyuan, Taiwan). The company listed on the TWSE in August 2024 and has received multiple Taiwan biotech innovation awards (Taipei Biotech Awards, Taiwan BIO Awards) in 2022-2024.

Formosa Pharmaceuticals firmographics

Firmographics
Name
Formosa Pharmaceuticals
Legal name
Formosa Pharmaceuticals, Inc.
Website
https://formosapharma.com
Company type
Public
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
Formosa Pharmaceuticals is a Taiwan-based clinical-stage biopharmaceutical company (TWSE: 6838) that develops ophthalmology and oncology drugs using its proprietary APNT® nanoparticle platform, commercializing its FDA-approved lead product APP13007 through a global out-licensing model covering 60+ countries.
Ownership category
akta.pro rank

Formosa Pharmaceuticals industry classification

Industry
Product category
Ophthalmic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Ophthalmic Goods (3851)
akta.pro industry
PRIMARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Ophthalmic pharmaceuticals
  • Nanoparticle drug formulation
  • Antibody-drug conjugates
  • Biopharmaceutical licensing
  • Post-surgical steroid therapies

Where Formosa Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Taipei
HQ country
Taiwan
HQ region
Asia

Offices3 records

Markets served

Formosa Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Licensing Revenue (Upfront, Milestones, Royalties): Formosa receives upfront payments, regulatory milestones, sales milestones, and ongoing royalties based on net sales of licensed products (primarily APP13007) across global territories. Licensing agreements signed with partners in US (Harrow), China (China Grand Pharma), South Korea (Samil), Australia/New Zealand (Arrotex), EU/Brazil (Adalvo), Canada/Mexico (Apotex), and others.
  2. Contract Manufacturing Supply: Formosa manufactures and supplies finished APP13007 product to licensing partners (e.g., Eyenovia/Harrow in US). Taiwan FDA (TFDA) granted export permit for US shipments. Manufacturing carried out by contract partners including Baudax Bio (formerly SpecGx) for API supply and Pharmasutics (Taoyuan facility) for fill-finish.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractLicensing deal terms include upfront payment, regulatory milestones, sales milestones, and royalties on net sales.

Go-to-market motion2 records

Distribution channels14 records

Marketing channels6 records

Formosa Pharmaceuticals product offering

Product offering

Core offering

Formosa Pharmaceuticals is a clinical-to-commercial stage biopharmaceutical company that develops, manufactures, and out-licenses ophthalmology and oncology therapeutics built on two proprietary platforms: the APNT® nanoparticle formulation technology and a bispecific antibody-drug conjugate (ADC) platform. Its lead commercial product is APP13007 (clobetasol propionate ophthalmic suspension 0.05%), an FDA-approved corticosteroid nanosuspension for post-operative ocular inflammation and pain following cataract surgery. Pipeline assets include APP13002 (antibiotic ocular formulation), TSY-110 (Kadcyla biosimilar), TSY-120, TSY-310 (EGFR/ROR1 bispecific ADC), and TSY-210 (anti-infective program).

Product overview

Formosa Pharmaceuticals is a clinical-stage biopharmaceutical company with a dual focus strategy ("Double A" strategy) encompassing ADC (antibody-drug conjugate) and APNT (nanoparticle) platforms. The product portfolio includes: APP13007, an FDA-approved ophthalmic corticosteroid for post-surgical inflammation and pain; APP13002, an antibiotic formulation for infectious eye diseases; TSY-110, a Kadcyla biosimilar for HER2-positive breast cancer; and TSY-310, a first-in-class bispecific ADC targeting EGFR/ROR1 for solid tumors. All ophthalmic products are powered by the proprietary APNT nanoparticle technology platform, which enables enhanced drug delivery through improved dissolution and bioavailability.

Differentiator

Problem solved

Functional benefit

Brands

  • APNT®: Active Pharmaceutical (ingredient) Nanoparticle Technology - proprietary nanoparticle formulation platform for enhancing dissolution and bioavailability of APIs
  • APP13007
  • TSY-110
  • TSY-310

Products and services

  • APP13007 (Clobetasol Propionate Ophthalmic Suspension 0.05%) FDA-approved topical corticosteroid nanosuspension derived from the proprietary APNT® nanoparticle formulation platform, delivered as a twice-daily dosing regimen for 14 days, indicated for the treatment of inflammation and pain following ocular surgery, particularly cataract surgery. Approved by FDA (March 2024) and Health Canada (March 2026). Phase 3 trials showed 80% of patients pain-free by day 4 and 60% achieving complete anterior chamber cell clearance (ACC=0) sustained from POD8 to POD15, with less than 2% adverse event rate.
  • APP13002 Antibiotic 505(b)(2) formulation developed using the APNT® nanoparticle technology platform for infectious eye diseases, designed to enhance drug delivery for ocular infections.
  • TSY-110 (ado-trastuzumab emtansine biosimilar) HER2-positive antibody-drug conjugate (ADC) biosimilar referencing Kadcyla® for treatment of metastatic HER2-positive breast cancer, developed using advanced antibody and bioconjugation technology through Taiwanese CDMO partners.
  • TSY-310 (ALM-401) First-in-class bispecific antibody-drug conjugate targeting both EGFR and ROR1 for the treatment of solid tumors, including non-small cell lung cancer (NSCLC). Features enhanced internalization and bystander cytotoxicity to address limitations of traditional single-target therapies.
  • TSY-120 ADC pipeline asset within Formosa Pharmaceuticals' antibody-drug conjugate pipeline.
  • TSY-210 (抗感染研發專案 | Anti-Infective R&D Project) Anti-infective research and development program within Formosa Pharmaceuticals' pipeline, focused on infectious disease therapeutics.

Quantifiable outcome

  • 80% of patients achieved complete pain relief within 4 days post-surgery (vs 50% with placebo); 60% achieved complete anterior chamber cell clearance (ACC=0) from POD8 sustained to POD15 (vs 4% placebo)
  • +3 more outcomes

Companies that use Formosa Pharmaceuticals

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Formosa Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Formosa Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

21 partnerships are on record, tiered core.

  • Samil Pharmaceutical Co., Ltd.coreChannel Partner/ Reseller/ Distributor · 1 June 2026Exclusive licensing agreement for commercialization of APP13007 in Vietnam. Building on January 2026 South Korea license. Deal includes upfront payment, regulatory milestones, and royalties. Vietnam has 300,000 cataract surgeries annually with 5% growth; ophthalmic corticosteroid market valued at $4.26 million USD in 2024. Samil pursuing regulatory approval and launch preparations in both markets.
  • Singapore Eye Research Institute (SERI)coreStrategic or Co-development Partner · 1 April 2026Strategic research collaboration announced April 30, 2026, to develop next-generation ophthalmic formulations for corneal and ocular surface diseases using Formosa's APNT® nanoparticle technology. Combines SERI's clinical research expertise (led by Associate Professor Yu-Chi Liu) with Formosa's drug delivery platform to enhance efficacy, bioavailability, and safety of topical ocular therapies.
  • Arrotex Pharmaceuticals Pty Ltd.coreChannel Partner/ Reseller/ Distributor · 1 February 2026Exclusive licensing agreement for commercialization of APP13007 in Australia and New Zealand. Deal includes upfront payments, regulatory milestones, sales milestones, and royalty considerations. Territory represents approximately 250,000 cataract surgeries annually. Arrotex fulfills 50% of Australia's total pharmaceutical volume and will leverage its national ophthalmology infrastructure.
  • Samil Pharmaceutical Co., Ltd.coreChannel Partner/ Reseller/ Distributor · 1 January 2026Exclusive licensing agreement for commercialization of APP13007 (clobetasol propionate ophthalmic suspension) in South Korea. Samil is a Korean pharmaceutical manufacturer (000520.KS) founded in 1947, specializing in ophthalmology, gastroenterology, and CNS. ~800,000 cataract surgeries annually in South Korea. Agreement includes upfront payment, sales milestones, and royalties. APP13007 is the first ophthalmic steroid to enter the Korean market since 2008.
  • Rxilient Medical Pte. Ltd.coreChannel Partner/ Reseller/ Distributor · 1 December 2025Exclusive licensing for major ASEAN markets: Singapore, Thailand, Indonesia, Philippines. Rxilient is a Singapore-based pharma company focused on emerging markets in Southeast Asia, Hong Kong, Macau, Taiwan, and MENA, with focus on ophthalmology, oncology, immunology, and internal medicine.
  • Harrow, Inc.coreChannel Partner/ Reseller/ Distributor · 1 June 2025Exclusive licensing agreement for US market commercialization of APP13007 (marketed as BYQLOVI™). Previously partnered with Eyenovia; rights transferred to Harrow in 2025. Harrow (NASDAQ: HROW) is a leading US ophthalmic pharmaceutical company. ~700,000 ophthalmic surgeries annually drive a ~USD 1.3 billion market.
  • Adalvo LimitedcoreChannel Partner/ Reseller/ Distributor · 1 May 2025Licensing for 39 European countries plus Brazil. Adalvo is a leading European B2B pharmaceutical company with partnerships in 130+ countries. European markets include UK, France, Germany, Spain, Italy, and other EU member states.
  • Almac DiscoverycoreStrategic or Co-development Partner · 1 May 2025In-licensing of ALM-401 (renamed TSY-310), a first-in-class bispecific ADC targeting EGFR/ROR1 for treatment of solid tumors including NSCLC. This adds a novel bispecific ADC to Formosa's oncology pipeline alongside TSY-110 (Kadcyla biosimilar).
  • Saval CorporationcoreChannel Partner/ Reseller/ Distributor · 1 April 2025Exclusive licensing for Chile and 8 emerging Latin American markets: Bolivia, Costa Rica, Guatemala, El Salvador, Honduras, Paraguay, Peru, Panama. Saval (headquartered in Santiago, Chile) operates across 14 Latin American countries with 85+ years of history.
  • Cipla LimitedcoreChannel Partner/ Reseller/ Distributor · 1 March 2025Multi-regional licensing for 11 emerging markets: India, Nepal, Sri Lanka, Bangladesh, Malaysia, Myanmar, Kenya, Nigeria, South Africa, Argentina, Colombia. Cipla is India's 3rd largest pharma company, #1 in South Africa prescription market, and #4 in US generics market.
  • Medvisis Switzerland AGcoreChannel Partner/ Reseller/ Distributor · 1 November 2024Exclusive licensing for Swiss market. Medvisis specializes in innovative medicines, rare disease treatments, and hospital pharmaceuticals, focusing on product registration and market access.
  • DÁVI FarmacêuticacoreChannel Partner/ Reseller/ Distributor · 1 October 2024Exclusive licensing for Portuguese market. DÁVI is a century-old company and major player in ophthalmology and ENT in Portugal. Partner of Pfizer for over 10 years (Xalacom, Xalatan). ~90,000 cataract surgeries annually in Portugal.
  • Baudax Bio / SpecGx (Mallinckrodt)coreOEM/ Whitelabel/ Licensing Partner · 1 September 2024API (active pharmaceutical ingredient) supply for APP13007. Baudax Bio (formerly SpecGx, a subsidiary of Mallinckrodt) supplies clobetasol propionate API for the FDA-approved ophthalmic suspension.
  • Apotex Inc.coreChannel Partner/ Reseller/ Distributor · 1 August 2024Exclusive licensing for Canadian market. Apotex is Canada's largest pharmaceutical company. Expanded to include Mexico in 2025.
  • Pharmasutics (Taoyuan) / Baudax GroupcoreOEM/ Whitelabel/ Licensing Partner · 1 June 2024Contract fill-finish manufacturing for APP13007. Pharmasutics (景德製藥) in Taoyuan, part of Baudax Group, handles filling and packaging of the ophthalmic suspension for US export. TFDA export permit obtained September 2024; first shipment to US completed September 2024.
  • AimMax Therapeutics, Inc.coreStrategic or Co-development Partner · 1 June 2024US-based co-development partner for APP13007 clinical development. Joint NDA submission to FDA (May 2023), which was accepted July 2023 with PDUFA date of March 4, 2024. AimMax contributed to clinical trial design, regulatory strategy, and FDA interactions. FDA approval obtained March 2024. AimMax is based in Research Triangle Park, North Carolina.
  • Tabuk Pharmaceuticals Manufacturing CompanycoreChannel Partner/ Reseller/ Distributor · 1 May 2024Exclusive licensing for Middle East and North Africa (17 countries). Tabuk is a leading Saudi Arabian pharmaceutical company with manufacturing facilities in Saudi Arabia, Sudan, and Algeria, and 2,400+ employees.
  • Cristália Produtos Químicos Farmacêuticos Ltda.coreChannel Partner/ Reseller/ Distributor · 1 January 2024Exclusive licensing for Brazilian market. Cristália is a Brazilian pharmaceutical company.
  • Eyenovia, Inc.coreStrategic or Co-development Partner · 1 February 2023Development collaboration combining Formosa's APNT® nanoparticle formulation platform with Eyenovia's Optejet® microdose drug delivery technology (MAP™ - Microdose Array Print). Co-development of acute dry eye disease treatment using clobetasol ophthalmic suspension with Optejet device. Started August 2024 in the US.
  • EirGenix Inc.coreStrategic or Co-development Partner · 1 March 2022Co-development alliance to develop TSY-0110 (EG12043 ado-trastuzumab emtansine biosimilar, Kadcyla®) for HER2-positive breast cancer. Taiwan's two major biopharma CDMOs provided antibody and bioconjugation technology.
  • China Grand Pharmaceutical and Healthcare Holdings LimitedcoreChannel Partner/ Reseller/ Distributor · 1 June 2021Exclusive licensing agreement for APP13007 in Mainland China, Hong Kong, and Macau. China Grand Pharma (HKEX: 00512) is one of China's largest ophthalmology companies with ~30 ophthalmic products covering prescription drugs, OTC, devices, and consumer health. NDA Phase 3 trial initiated in China Q4 2024.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Formosa Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Aldeyra Therapeutics: Aldeyra Therapeutics is a clinical-stage biotech developing novel treatments for ocular inflammatory diseases (dry eye, allergic conjunctivitis). Comparable as a small-cap ophthalmic-focused biotech with innovative therapeutics targeting post-operative and chronic ocular inflammation.
  • Tarsus Pharmaceuticals: Tarsus Pharmaceuticals is a US biopharmaceutical company developing and commercializing novel therapeutics for eye diseases, including post-surgical and ocular surface conditions. Comparable as a small-cap specialty ophthalmic pharma with a recently commercialized product in similar therapeutic indications.
  • Ocular Therapeutix: Ocular Therapeutix is a US-based biopharmaceutical company developing therapies for eye diseases using a proprietary hydrogel technology platform. Comparable as a small ophthalmic pharma commercializing innovative drug delivery-based products in the same therapeutic categories.
  • Ocugen: Ocugen is a US-based biopharmaceutical company developing gene therapies and novel biologics for ophthalmic diseases. Comparable as a small-cap ophthalmic-focused biotech with a multi-platform strategy and global licensing ambitions.
  • Kala Bio: Kala Bio is a clinical-stage biopharmaceutical company developing novel therapies for eye diseases using a proprietary mucus-penetrating particle technology platform. Comparable as a small ophthalmic biotech leveraging a differentiated drug delivery technology platform.
  • Eyenovia: Eyenovia is a US ophthalmic therapeutics company that was Formosa's original US development partner for APP13007 (using its Optejet® microdose delivery platform). Comparable as a small-cap ophthalmic specialty pharma with innovative delivery approaches targeting the same prescriber base.
  • Harrow Health: Harrow Health (NASDAQ: HROW) is a US specialty ophthalmic pharmaceutical company that is both Formosa's US commercial partner for APP13007 (BYQLOVI™) and a comparable specialty ophthalmic pharma focused on commercializing innovative therapies in the same end market.
  • Nicox SA: Nicox is a European specialty ophthalmic pharmaceutical company developing therapeutics for ocular conditions including glaucoma and dry eye. Comparable as a small-to-mid cap specialty ophthalmic pharma with similar licensing-driven business model and end-market focus.

Emerging players

  • Aurinia Pharmaceuticals: Aurinia Pharmaceuticals is a small-cap biopharma that has commercialized a specialty therapeutic (voclosporin) through global licensing deals with partners like Otsuka. Comparable business model of out-licensing a single approved asset to global commercial partners for milestone/royalty economics.

Regional players

  • Samil Pharmaceutical: Samil Pharmaceutical (000520.KS) is a Korean pharmaceutical manufacturer that became Formosa's exclusive licensee for APP13007 in Korea and Vietnam. Comparable as a regional specialty pharma with ophthalmology focus, though primarily a partner rather than direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Formosa Pharmaceuticals social profiles

Digital presence

Formosa Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Formosa Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles10 records

Formosa Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Formosa Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Formosa Pharmaceuticals

What does Formosa Pharmaceuticals do?

Formosa Pharmaceuticals is a clinical-to-commercial stage biopharmaceutical company that develops, manufactures, and out-licenses ophthalmology and oncology therapeutics built on two proprietary platforms: the APNT® nanoparticle formulation technology and a bispecific antibody-drug conjugate (ADC) platform. Its lead commercial product is APP13007 (clobetasol propionate ophthalmic suspension 0.05%), an FDA-approved corticosteroid nanosuspension for post-operative ocular inflammation and pain following cataract surgery. Pipeline assets include APP13002 (antibiotic ocular formulation), TSY-110 (Kadcyla biosimilar), TSY-120, TSY-310 (EGFR/ROR1 bispecific ADC), and TSY-210 (anti-infective program).

Is Formosa Pharmaceuticals a public or private company?

Formosa Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Formosa Pharmaceuticals founded?

Formosa Pharmaceuticals was founded in 2011. It employs 11 to 50 people.

Where is Formosa Pharmaceuticals based?

Formosa Pharmaceuticals is headquartered in Taipei, Taiwan, in the Asia region.

How does Formosa Pharmaceuticals make money?

Two revenue lines are on record. Licensing Revenue (Upfront, Milestones, Royalties) is the primary driver. The others are contract Manufacturing Supply.

Who are Formosa Pharmaceuticals's main competitors?

Direct peers on record are Aldeyra Therapeutics, Tarsus Pharmaceuticals, Ocular Therapeutix, Ocugen, Kala Bio, Eyenovia, Harrow Health and Nicox SA. Aurinia Pharmaceuticals is listed as an emerging player. Samil Pharmaceutical is listed as a regional player.

Does Formosa Pharmaceuticals have an API?

No public API is recorded for Formosa Pharmaceuticals.

What industry is Formosa Pharmaceuticals in?

Formosa Pharmaceuticals's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAL, Ophthalmology Pharmaceuticals, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
뉴스톱삼일제약, 100억 CB로 베트남 안과 시장 베팅 - 뉴스톱Samil Pharmaceutical issued 100 billion KRW convertible bonds to fund its expansion in Vietnam's ophthalmology market. The company signed an exclusive distribution deal with Formosa Pharmaceuticals for its APP13007 eye drop, and its largest shareholder increased holdings. The funds will support a CMO factory and repay existing bonds.PR NewswireFormosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and PTaiwan-based Formosa Pharmaceuticals announced an exclusive licensing agreement with South Korea's Samil Pharmaceuticals for commercialization of its FDA-approved eye treatment APP13007 (clobetasol propionate ophthalmic suspension) in Vietnam. The deal includes upfront payment, regulatory milestones, and royalties, covering a market where cataract surgeries reach 300,000 annually with 5% annual growth and the ophthalmic corticosteroid market valued at $4.26 million USD in 2024. The agreement builds on a January 2026 license for South Korea, with Samil pursuing regulatory approval and launch preparations across both markets to strengthen its global ophthalmology business.PR NewswireFormosa Pharmaceuticals Announces Presentation of TSY-310 at the 2026 ASCO Annual MeetingFormosa Pharmaceuticals announced that its abstract on TSY-310, a novel bispecific antibody-drug conjugate targeting EGFR and ROR1, has been selected for presentation at the 2026 ASCO Annual Meeting in Chicago. The poster will highlight preclinical efficacy data demonstrating the ADC's ability to eradicate antigen-negative tumor cells through enhanced internalization and bystander cytotoxicity. The company's CEO stated the selection acknowledges the program's potential to address limitations of traditional single-target therapies for advanced solid tumors.PR NewswireFormosa Pharmaceuticals and Singapore Eye Research Institute (SERI) Partner to Advance Novel Ophthalmic Formulations for Corneal DiseasesFormosa Pharmaceuticals and the Singapore Eye Research Institute (SERI) announced a strategic research collaboration on April 30, 2026, to develop next-generation ophthalmic formulations for corneal and ocular surface diseases using Formosa's proprietary APNT® nanoparticle technology. The partnership will combine SERI's clinical research expertise, led by Associate Professor Yu-Chi Liu, with Formosa's drug delivery platform to enhance the efficacy, bioavailability, and safety of topical ocular therapies. Initial research efforts have confirmed compatibility between the technologies, prompting the extension of the partnership from initial testing to a broader collaboration.BioSpaceFormosa Pharmaceuticals and Singapore Eye Research Institute (SERI) Partner to Advance Novel Ophthalmic Formulations for Corneal DiseasesFormosa Pharmaceuticals and the Singapore Eye Research Institute announced a collaboration to develop next-generation ophthalmic formulations for corneal diseases. The partnership combines Formosa's APNT nanoparticle technology with SERI's clinical research expertise to improve drug delivery and patient outcomes.openPR.comAnalysis of Segments and Major Growth Areas in the Post-Operative Cataract Surgery Inflammation Treatment MarketThe post-operative cataract surgery inflammation treatment market is projected to reach $6.78 billion by 2030, growing at a 7.2% CAGR, driven by rising demand for advanced ophthalmic drug formulations and increased investments in ophthalmology research. In September 2024, Armistice Capital LLC acquired Eyenovia Inc., strengthening its position in the ophthalmic field. In March 2024, Taiwan's Formosa Pharmaceuticals, in partnership with AimMax Therapeutics, received FDA approval for APP13007 (clobetasol propionate ophthalmic suspension 0.05%), the first new ophthalmic steroid approved by the FDA in over 15 years.PR NewswireFormosa Pharmaceuticals Announces Licensing Agreement with Arrotex, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular SurTaiwan-based Formosa Pharmaceuticals entered an exclusive licensing agreement with Arrotex Pharmaceuticals Pty Ltd for commercialization of its FDA-approved clobetasol propionate ophthalmic suspension (APP13007) in Australia and New Zealand, covering treatment of inflammation and pain following ocular surgery. The deal includes upfront payments, regulatory milestones, sales milestones, and royalty considerations, with the territory representing approximately 250,000 cataract surgeries annually. Arrotex, which fulfills 50% of Australia's total pharmaceutical volume, will leverage its national ophthalmology infrastructure to distribute the product to patients recovering from ocular surgery.PR NewswireFormosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and PTaiwan-based Formosa Pharmaceuticals has entered into an exclusive licensing agreement with South Korea's Samil Pharmaceuticals for the commercialization of clobetasol propionate ophthalmic suspension (APP13007), a US FDA-approved patented medicine for treating inflammation and pain following ocular surgery, in South Korea. The agreement includes upfront payment, sales milestones, and royalties, with APP13007 representing the first ophthalmic steroid to enter the South Korean market since 2008, targeting a market of nearly 800,000 cataract surgeries annually. The partnership builds on a prior CMO agreement executed between the two companies in 2024 and leverages Samil's established leadership in ophthalmology to serve Korean ocular surgery patients.PR NewswireFormosa Pharmaceuticals Announces Licensing Agreement with Rxilient, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular SuFormosa Pharmaceuticals has entered into an exclusive licensing agreement with Rxilient Medical to commercialize its ophthalmic drug APP13007 in key ASEAN regions. The deal covers Indonesia, the Philippines, Singapore, and Thailand for the treatment of inflammation and pain following ocular surgery, leveraging Formosa's FDA-approved nanoparticle formulation platform. This partnership aims to address a market with over 1 million annual ocular surgeries through upfront payments and milestone structures.